Joop van Gerven
Hoogleraar Klinische Neuropsychofarmacologie
- Naam
- Prof.dr. J.M.A. van Gerven
- Telefoon
- +31 71 526 9111
- j.m.a.van_gerven@lumc.nl
- ORCID iD
- 0000-0002-1444-7415
- Hoogleraar klinische neuropsychofarmacologie - Voorzitter Centrale Commissie Mensgebonden Onderzoek (CCMO)
- Hoogleraar klinische neuropsychofarmacologie
- Voorzitter Centrale Commissie Mensgebonden Onderzoek (CCMO)
Klinische neuropsychofarmacologie
De leerstoel klinische neurofarmacologie is gericht op onderzoek naar geneesmiddelen voor aandoeningen van het centrale zenuwstelsel, en op de ontwikkeling van methoden om deze middelen te onderzoeken. Daarnaast wordt klinisch neuropsychofarmacologisch) onderwijs ontwikkeld en gegeven aan studenten en assistenten in opleiding tot neuroloog, psychiater of apotheker.
Deze activiteiten worden uitgevoerd vanuit het Centre for Human Drug Research (CHDR), in nauwe samenwerking met innovatieve farmaceutische bedrijven en met klinische afdelingen binnen het LUMC (m.n. psychiatrie, neurologie, anesthesie); alsmede met andere Leidse onderzoeksinstellingen (LACDR (PK/PD-modeling), LIBC (fMRI)) en universiteiten (m.n. Technische Universiteit Twente (neurofysiologie), en Universiteit Maastricht (psychofarmacologie)).
Academische leerweg
Joop van Gerven promoveerde in 1990 in Leiden op een proefschrift over diabetes mellitus. Zijn opleiding neurologie volgde hij aan wat nu het Erasmus MC Rotterdam heet. Vanaf 1994 werkte hij bijna 25 jaar als neuroloog in het LUMC.
In 1994 werd hij ook Director CNS Research bij het CHDR in Leiden. In 1997 werd hij formeel gecertificeerd als klinisch farmacoloog.
Sinds 2004 is hij hoogleraar klinische neuropsychofarmacologie aan de Universiteit Leiden. Op 21 juni 2005 sprak hij zijn oratie uit, getiteld ‘Het Benevelde Brein’.
Hij publiceerde meer dan 200 artikelen en hoofdstukken over vroege ontwikkeling van geneesmiddelen voor aandoeningen van het centrale zenuwstelsel.
Hij is bestuurslid geweest van diverse binnen- en buitenlandse wetenschappelijke organisaties, redactielid van tijdschriften, en was en is in allerlei hoedanigheden (organisator, presentator, sessievoorzitter) actief bij een groot aantal congressen en symposia.
Sinds 2011 is hij als klinisch farmacoloog-lid en vicevoorzitter aan de CCMO verbonden, en sinds 2016 als voorzitter van de commissie.
Hoogleraar Klinische Neuropsychofarmacologie
- Faculteit Geneeskunde
- Divisie 3
- Neurologie
- Recourt, K.; Boer, P. de; Ark, P. van der; Benes, H.; Gerven, J.M.A. van; Ceusters, M.; Nueten, L. van; Drevets, W.C.; Bhatacharya, A.; Browning, M. & Jacobs, G.E. (2023), Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder, Translational Psychiatry 13(1).
- Prins, S.; Borghans, L.; Kam, M.L. de; Groeneveld, G.J. & Gerven, J. van (2023), Cognitive performance in healthy clinical trial participants and patients with the NeuroCart, a neurodegenerative disease measured with an automated neuropsychological and neurophysiological test battery, Journal of the Neurological Sciences 449.
- Dijkstra, F.; O'Donnell, P.; Klaassen, E.; Buhl, D.; Asgharnejad, M.; Rosen, L.; Zuiker, R.; Gerven, J. van & Jacobs, G. (2022), Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers, Translational Psychiatry 12(1).
- Baakman, A.C.; Gavan, C.; Doeselaar, L. van; Kam, M. de; Broekhuizen, K.; Bajenaru, O.; Camps, L.; Swart, E.L.; Kalisvaart, K.; Schoonenboom, N.; Lemstra, E.; Scheltens, P.; Cohen, A.; Gerven, J. van & Groeneveld, G.J. (2022), Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease, British Journal of Clinical Pharmacology 88(6).
- Dijkstra, F.M.; Zuiker, R.G.J.A.; Siebenga, P.S.; Leigh-Pemberton, R.A.; Sun, L.; Manthis, J.D.; Kam, M.L.; Lin, R.; Moltke, L.L.; Rezendes, D. & Gerven, J.M.A. (2022), Pharmacological profile of ALKS 7119, an investigational compound evaluated for the treatment of neuropsychiatric disorders, in healthy volunteers, British Journal of Clinical Pharmacology 88(6).
- Dankers, M.; Nelissen-Vrancken, H.; Berger, M. Y.; Bonten, M. J. M.; Gerven, J. M. A. van; Kunst, P. W. A.; Muller, M.; Rikkert, M. G. M. Olde & Rosendaal, F. R. (2022), Recente en toekomstige behandelingen bij covid-19, Nederlands Tijdschrift voor Geneeskunde 166.
- Brooks, S.; Zuiker, R.G.J.A.; Jacobs, G.E.; Kezic, I.; Savitz, A.; Ark, P.D. van der & Gerven, J.M.A. van (2021), ACUTE EFFECTS OF SELTOREXANT, A SELECTIVE OREXIN-2 ANTAGONIST (JNJ-42847922), ON DRIVING AFTER BEDTIME ADMINISTRATION, SLEEP 44: A136-A136.
- Guan, Z.; Chen, X.G.; Hay, J.; Gerven, J. van; Burggraaf, J. & Kam, M. de (2021), Stability analysis of clustering of Norris' visual analogue scale, Medicine 100(17).
- Bakker, C.; Esdonk, M.J. van; Stuurman, R.E.; Borghans, L.G.J.M.; Kam, M.L. de; Gerven, J.M.A. van & Groeneveld, G.J. (2021), Biperiden challenge model in healthy elderly as proof-of-pharmacology tool, Journal of Clinical Pharmacology 61(11): 1466-1478.
- Vissers, M.F.J.M.; Cohen, A.F.; Gerven, J.M.A. van & Groeneveld, G.J. (2020), The impact of the global COVID-19 pandemic on the conduct of clinical trials, British Journal of Clinical Pharmacology 87(3).
- Muehlan, C.; Boehler, M.; Brooks, S.; Zuiker, R.; Gerven, J. van & Dingemanse, J. (2020), Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration, Journal of Psychopharmacology 34(3): 326-335.
- Recourt, K.; Aart, J. van der; Jacobs, G.; Kam, M. de; Drevets, W.; Nueten, L. van; Kanhai, K.; Siebenga, P.; Zuiker, R.; Ravenstijn, P.; Timmers, M.; Gerven, J. van & Boer, P. de (2020), Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial, Journal of Psychopharmacology 34(9): 1030-1042.
- Leijenaar, J.F.; Groeneveld, G.J.; Klaassen, E.S.; Leeuwis, A.E.; Scheltens, P.; Weinstein, H.C.; Gerven, J.M.A. van; Barkhof, F.; Flier, W.M. van der & Prins, N.D. (2020), Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI, Alzheimer's Research and Therapy 12(1).
- Guan, Z.; Jacobs, G.; Pelt, H. van; Gerven, J.M.A. van; Burggraaf, J. & Zhao, W. (2020), PK/PD modeling of 5-hydroxytryptophan (5-HTP) challenge test with cortisol measurement in serum and saliva, Pharmacology Research and Perspectives 8(2).
- Brooks, S.; Jacobs, G.E.; Boer, P. de; Kent, J.M.; Nueten, L. van; Amerongen, G. van; Zuiker, R.; Kezic, I.; Luthringer, R.; Ark, P. van der; Gerven, J.M.A. van & Drevets, W. (2019), The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia, Journal of Psychopharmacology 33(2): 202-209.
- Recourt, K.; Boer, P. de; Zuiker, R.; Luthringer, R.; Kent, J.; Ark, P. van der; Hove, I. van; Gerven, J. van; Jacobs, G.; Nueten, L. van & Drevets, W. (2019), The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder (vol 9, 216, 2019), Translational Psychiatry 9.
- Recourt, K.; Boer, P. de; Zuiker, R.; Luthringer, R.; Kent, J.; Ark, P. van der; Hove, I. van; Gerven, J. van; Jacobs, G.; Nueten, L. van & Drevets, W. (2019), The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder, Translational Psychiatry 9.
- Muehlan, C.; Brooks, S.; Zuiker, R.; Gerven, J. van & Dingemanse, J. (2019), Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration, European Neuropsychopharmacology 29(7): 847-857.
- Muehlan, C.; Fischer, H.; Zimmer, D.; Aissaoui, H.; Grimont, J.; Boss, C.; Croft, M.; Gerven, J. van; Krahenbuhl, S. & Dingemanse, J. (2019), Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/Accelerator Mass Spectrometry, Current Drug Metabolism 20(4): 254-265.
- Chen, X.; Gerven, J. van; Cohen, A. & Jacobs, G. (2019), Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety, Acta Pharmacologica Sinica 40(5): 571-582.
- Muehlan C, Zuiker R, Brooks S, van Gerven J & Dingemanse J (2019), CLINICAL PHARMACOLOGY OF THE DUAL OREXIN RECEPTOR ANTAGONIST ACT-541468 IN ELDERLY SUBJECTS.
- Klaassens, B.L.; Gerven, J.M.A. van; Klaassen, E.S.; Grond, J. van der & Rombouts, S.A.R.B. (2019), Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease, NeuroImage 199: 143-152.
- Hart, E.P.; Alvarez-Jimenez, R.; Davidse, E.; Doll, R.J.; Cohen, A.F.; Gerven, J.M.A. van & Groeneveld, G.J. (2019), A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development, Journal of Visualized Experiments.
- Brussee J.M., Vet N.J., Krekels E.H.J., Valkenburg A.J., Jacqz-Aigrain E., Gerven J.M.A. van, Swart E.L., Anker J.N. van den, Tibboel D., Hoog M. de, Wildt S.N. de & Knibbe C.A.J. (2018), Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure, British Journal of Clinical Pharmacology 84(2): 358-368.
- Klaassens, B.L.; Gerven, J.M.A. van; Klaassen, E.S.; Grond, J. van der & Rombouts, S.A.R.B. (2018), Serotonergic and cholinergic modulation of functional brain connectivity: A comparison between young and older adults, NeuroImage 169: 312-322.
- Muehlan C., Brooks S., Zuiker R., van Gerven J. & Dingemanse J. (2018), NIGHT-TIME ADMINISTRATION OF ACT-541468, A NOVEL DUAL OREXIN RECEPTOR ANTAGONIST: CHARACTERIZATION OF ITS PHARMACOKINETICS, NEXT-DAY RESIDUAL EFFECTS, SAFETY, AND TOLERABILITY, SLEEP 41: A3-A3.
- Doef, T.F. van der; Domingo, S.Z.; Jacobs, G.E.; Drevets, W.C.; Marston, H.M.; Nathan, P.J.; Tome, M.B.; Tamminga, C.A.; Gerven, J.M.A. van & Kas, M.J.H. (2018), New approaches in psychiatric drug development, European Neuropsychopharmacology 28(9): 983-993.
- Muehlan C., Brooks S., Zuiker R., van Gerven J. & Dingemanse J. (2018), MULTIPLE-ASCENDING-DOSE STUDY OF ACT-541468, A NOVEL DUAL OREXIN RECEPTOR ANTAGONIST: CHARACTERIZATION OF ITS MULTIPLE-DOSE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY, SLEEP 41: A3-A3.
- Gerven, J. van & Cohen, A. (2018), Integrating data from the Investigational Medicinal Product Dossier/investigator's brochure. A new tool for translational integration of preclinical effects, British Journal of Clinical Pharmacology 84(7): 1457-1466.
- Huizinga, C.R.H.; Kam, M.L. de; Stockmann, H.B.A.C.; Gerven, J.M.A. van; Cohen, A.F. & Bogt, K.E.A. van der (2018), Evaluating Fitness to Perform in Surgical Residents after Night Shifts and Alcohol Intoxication: The development of a "Fit-to-Perform" test, Journal of Surgical Education 75(4): 968-977.
- Morrison, R.L.; Fedgchin, M.; Singh, J.; Gerven, J. van; Zuiker, R.; Lim, K.S.; Ark, P. van der; Wajs, E.; Xi, L.W.; Zannikos, P. & Drevets, W.C. (2018), Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study, Psychopharmacology 235(4): 1107-1119.
- Jacobs Milou, Hart Ellen P., Miranda Yuri Mejia, Groeneveld Geert Jan, van Gerven Joop M. A. & Roos Raymund A. C. (2018), DRIVING PERFORMANCE OF HUNTINGTON'S DISEASE GENE CARRIERS, Journal of Neurology, Neurosurgery and Psychiatry 89: A87-A87.
- Boer, P. de; Drevets, W.C.; Rofael, H.; Ark, P. van der; Kent, J.M.; Kezic, I.; Parapatics, S.; Dorffner, G.; Gerven, J. van; Benes, H.; Keicher, C.; Jahn, H.; Seiden, D.J. & Luthringer, R. (2018), A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity, Journal of Psychopharmacology 32(6): 668-677.
- Jacobs, M.; Hart, E.P.; Miranda, Y.M.; Groeneveld, G.J.; Gerven, J.M.A. van & Roos, R.A.C. (2018), Altered driving performance of symptomatic Huntington's disease gene carriers in simulated road conditions, Traffic Injury Prevention 19(7): 708-714.
- Muehlan, C.; Heuberger, J.; Juif, P.E.; Croft, M.; Gerven, J. van & Dingemanse, J. (2018), Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study, Clinical Pharmacology and Therapeutics 104(5): 1022-1029.
- Nickolls, S.A.; Gurrell, R.; Amerongen, G. van; Kammonen, J.; Cao, L.S.; Brown, A.R.; Stead, C.; Mead, A.; Watson, C.; Hsu, C.; Owen, R.M.; Pike, A.; Fish, R.L.; Chen, L.G.; Qiu, R.L.; Morris, E.D.; Feng, G.; Whitlock, M.; Gorman, D.; Gerven, J. van; Reynolds, D.S.; Dua, P. & Butt, R.P. (2018), Pharmacology in translation: the preclinical and early clinical profile of the novel alpha 2/3 functionally selective GABA(A) receptor positive allosteric modulator PF-06372865, British Journal of Pharmacology 175(4): 708-725.
- Klaassens B.L., Rombouts S.A.R.B., Winkler A.M., Van Gorsel H.C., Van der Grond J. & Gerven J.M.A. van. (2017), Time related effects on functional brain connectivity after serotonergic and cholinergic neuromodulation, Human Brain Mapping 38(1): 308-325.
- Baakman A.C., Alvarez-Jimenez R., Rissmann R., Klaassen E.S., Stevens J., Goulooze S.C., Burger J.C.G. den, Swart E.L., Gerven J.M.A. van & Groeneveld G.J. (2017), An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine, British Journal of Clinical Pharmacology 83(8): 1676-1687.
- Elzen, W.P.J. den; Gerven, J. van; Schenk, P.W.; Boogaard, A.U. den; Kroon, R.; Klaassen, E.; Ballieux, B.E.P.B. & Cobbaert, C.M. (2017), How to define reference intervals to rule in healthy individuals for clinical trials?, Clinical Chemistry and Laboratory Medicine 55(3): E59-E61.
- Baakman, A.C.; Alvarez-Jimenez, R.; Rissmann, R.; Klaassen, E.S.; Stevens, J.; Goulooze, S.C.; Burger, J.C.G. den; Swart, E.L.; Gerven, J.M.A. van & Groeneveld, G.J. (2017), An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine, British Journal of Clinical Pharmacology 83(8): 1676-1687.
- Khalili-Mahani, N.; Rombouts, S.A.R.B.; Osch, M.J.P. van; Duff, E.P.; Carbonell, F.; Nickerson, L.D.; Becerra, L.; Dahan, A.; Evans, A.C.; Soucy, J.P.; Wise, R.; Zijdenbos, A.P. & Gerven, J.M. van (2017), Biomarkers, Designs, and Interpretations of Resting-State fMRI in Translational Pharmacological Research: A Review of State-of-the-Art, Challenges, and Opportunities for Studying Brain Chemistry, Human Brain Mapping 38(4): 2276-2325.
- Klaassens, B.L.; Gerven, J.M.A. van; Grond, J. van der; Vos, F. de; Moller, C. & Rombouts, S.A.R.B. (2017), Diminished Posterior Precuneus Connectivity with the Default Mode Network Differentiates Normal Aging from Alzheimer's Disease, Frontiers in Aging Neuroscience 9.
- Wilhelmus, M.M.M.; Hay, J.L.; Zuiker, R.G.J.A.; Okkerse, P.; Perdrieu, C.; Sauser, J.; Beaumont, M.; Schmitt, J.; Gerven, J.M.A. van & Silber, B.Y. (2017), Effects of a single, oral 60 mg caffeine dose on attention in healthy adult subjects, Journal of Psychopharmacology 31(2): 222-232.
- Recourt, K.; Amerongen, G. van; Jacobs, G.; Zuiker, R.; Luthringer, R.; Ark, P. van der & Gerven, J. van (2017), JNJ-42847922/MIN-202, a selective orexin 2 receptor antagonist, demonstrates beneficial effects on mood and sleep in patients with major depressive disorder, European Neuropsychopharmacology 27: S866-S866.
- Chen, X.; Broeyer, F.; Kam, M. de; Baas, J.; Cohen, A. & Gerven, J. van (2017), Pharmacodynamic response profiles of anxiolytic and sedative drugs, British Journal of Clinical Pharmacology 83(5): 1028-1038.
- Schrier, L.; Zuiker, R.; Merkus, F.W.H.M.; Klaassen, E.S.; Guan, Z.; Tuk, B.; Gerven, J.M.A. van; Geest, R. van der & Groeneveld, G.J. (2017), Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation, British Journal of Clinical Pharmacology 83(4): 721-731.
- Alvarez-Jimenez, R.; Baakman, A.C.; Stevens, J.; Goulooze, S.C.; Hart, E.P.; Rissmann, R.; Gerven, J.M.A. van & Groeneveld, G.J. (2017), Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation, Journal of Psychopharmacology 31(2): 192-203.
- Kruithof, A.C.; Watanabe, S.; Peeters, P.A.M.; Kam, M.L. de; Zuiker, R.G.J.A.; Stevens, J.; Gerven, J.M.A. van & Stockis, A. (2017), Pharmacological interactions between brivaracetam and ethanol in healthy males, Journal of Psychopharmacology 31(7): 915-926.
- Klaassens, B.L.; Rombouts, S.A.R.B.; Winkler, A.M.; Gorsel, H.C. van; Grond, J. van der & Gerven, J.M.A. van (2017), Time related effects on functional brain connectivity after serotonergic and cholinergic neuromodulation, Human Brain Mapping 38(1): 308-325.
- Loo, A.J.A.E. van de; Bervoets, A.C.; Mooren, L.; Bouwmeester, N.H.; Garssen, J.; Zuiker, R.; Amerongen, G. van; Gerven, J. van; Singh, J.; Ark, P. van der; Fedgchin, M.; Morrison, R.; Wajs, E. & Verster, J.C. (2017), The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study, Psychopharmacology 234(21): 3175-3183.
- Brooks, S.; Siebenga, P.; Zuiker, R.; Jacobs, G.; Kezic, I.; Gerven, J. van; Luthringer, R.; Boer, P. de & Ark, P. van der (2017), The selective orexin-2 antagonist JNJ-42847922(MIN-202) improves sleep in patients with primary insomnia, European Neuropsychopharmacology 27: S655-S656.
- Treiber, A.; Kanter, R. de; Roch, C.; Gatfield, J.; Boss, C.; Raumer, M. von; Schindelholz, B.; Muehlan, C.; Gerven, J. van & Jenck, F. (2017), The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468, Journal of Pharmacology and Experimental Therapeutics 362(3): 489-503.
- Alvarez-Jimenez R., 't Hart E. P., Prins S., de Kam M., van Gerven J. M., Cohen A. & Groeneveld G. (2017), REVERSAL OF MECAMYLAMINE-INDUCED EFFECTS IN HEALTHY SUBJECTS BY NICOTINE RECEPTOR AGONISTS: COGNITIVE AND (ELECTRO) PHYSIOLOGICAL RESPONSES., Clinical Pharmacology and Therapeutics 101(S1): S43-S43.
- Boehler M., Muehlan C., Juif P. -E., English S., van Gerven J., Peeters P., Heuberger J. & Dingemanse J. (2017), MASS BALANCE AND ABSOLUTE BIOAVAILABILITY OF ACT-541468, A DUAL OREXIN RECEPTOR ANTAGONIST, BY ADMINISTRATION OF A MICROTRACER DOSE AND AMS ANALYSIS IN A FIRST-IN-HUMAN STUDY., Clinical Pharmacology and Therapeutics 101(S1): S57-S57.
- Muehlan C., Juif P. -E., van Gerven J., Heuberger J. & Dingemanse J. (2017), FIRST-IN-HUMAN STUDY OF ACT-541468, A NOVEL DUAL OREXIN RECEPTOR ANTAGONIST: CHARACTERIZATION OF ITS PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY, Clinical Pharmacology and Therapeutics 101(S1): S80-S80.
- Alvarez-Jimenez R., Groeneveld G.J., Gerven J.M. van, Goulooze S.C., Baakman A.C., Hay J.L. & Stevens J. (2016), Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects, British Journal of Clinical Pharmacology 82: 1011-1021.
- Spiegelstein, O.; Stevens, J.; Gerven, J. van; Nathan, P.J.; Maynard, J.P.; Mayleben, D.W.; Hellriegel, E. & Yang, R.H. (2016), Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects, Journal of Psychopharmacology 30(10): 983-993.
- Guan, Z.; Klumpers, L.E.; Oyetayo, O.O.; Heuberger, J.; Gerven, J.M.A. van & Stevens, J. (2016), Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on (9)-tetrahydrocannabinol challenge tests, British Journal of Clinical Pharmacology 81(4): 713-723.
- Zuiker, R.G.J.A.; Chen, X.; Osterberg, O.; Mirza, N.R.; Muglia, P.; Kam, M. de; Klaassen, E.S. & Gerven, J.M.A. van (2016), NS11821, a partial subtype-selective GABA(A) agonist, elicits selective effects on the central nervous system in randomized controlled trial with healthy subjects, Journal of Psychopharmacology 30(3): 253-262.
- Alvarez-Jimenez, R.; Groeneveld, G.J.; Gerven, J.M.A. van; Goulooze, S.C.; Baakman, A.C.; Hay, J.L. & Stevens, J. (2016), Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects, British Journal of Clinical Pharmacology 82(4): 1011-1021.
- Chen, X.; Jacobs, G.; Kam, M.L. de; Jaeger, J.; Lappalainen, J.; Maruff, P.; Smith, M.A.; Cross, A.J.; Cohen, A. & Gerven, J. van (2015), AZD6280, a Novel Partial gamma-Aminobutyric Acid A Receptor Modulator, Demonstrates a Pharmacodynamically Selective Effect Profile in Healthy Male Volunteers, Journal of Clinical Psychopharmacology 35(1): 22-33.
- Baakman A. C., Rissmann R., Klaassen E. S., van Gerven J. M. A. & Groeneveld G. J. (2015), PK AND PD OF A NICOTINIC ANTICHOLINERIC CHALLENGE WITH MECAMYLAMINE IN COMPARISON TO SCOPOLAMINE, Clinical Therapeutics 37(8): E10-E11.
- Cohen, A.F.; Burggraaf, J.; Gerven, J.M.A. van; Moerland, M.; Groeneveld, G.J. & Insel, P.A. (2015), The Use of Biomarkers in Human Pharmacology (Phase I) Studies, Annual Review of Pharmacology and Toxicology 55: 55-+.
- Beek, E.T. te; Chen, X.; Jacobs, G.E.; Nahon, K.J.; Kam, M.L. de; Lappalainen, J.; Cross, A.J.; Gerven, J.M.A. van & Hay, J.L. (2015), The Effects of the Nonselective Benzodiazepine Lorazepam and the alpha(2)/alpha(3) Subunit-Selective GABA(A) Receptor Modulators AZD7325 and AZD6280 on Plasma Prolactin Levels, Clinical Pharmacology in Drug Development 4(2): 149-154.
- Roozekrans, M.; Olofsen, E.; Schrier, R. van der; Gerven, J. van; Peng, S.; McLeod, J. & Dahan, A. (2015), Reversal of opioid-induced respiratory depression by BK-channel blocker GAL021: A pharmacokinetic-pharmacodynamic modeling study in healthy volunteers, Clinical Pharmacology and Therapeutics 97(6): 641-649.
- Heuberger, J.A.A.C.; Guan, Z.; Oyetayo, O.O.; Klumpers, L.; Morrison, P.D.; Beumer, T.L.; Gerven, J.M.A. van; Cohen, A.F. & Freijer, J. (2015), Population Pharmacokinetic Model of THC Integrates Oral, Intravenous, and Pulmonary Dosing and Characterizes Short- and Long-term Pharmacokinetics, Clinical Pharmacokinetics 54(2): 209-219.
- Kleinloog, D.; Boogaard, A.U. den; Dahan, A.; Mooren, R.; Klaassen, E.; Stevens, J.; Freijer, J. & Gerven, J. van (2015), Optimizing the glutamatergic challenge model for psychosis, using S(+)-ketamine to induce psychomimetic symptoms in healthy volunteers, Journal of Psychopharmacology 29(4): 401-413.
- Kleinloog, D.; Stevens, J.; Heuberger, J.; Spinhoven, P. & Gerven, J. van (2014), The influence of personality on the sensitivity to subjective effects of Delta(9)-tetrahydrocannabinol, Psychiatry Research 220(3): 945-953.
- Chen, X.; Jacobs, G.; Kam, M. de; Jaeger, J.; Lappalainen, J.; Maruff, P.; Smith, M.A.; Cross, A.J.; Cohen, A. & Gerven, J. van (2014), The central nervous system effects of the partial GABA-A alpha(2,3)-selective receptor modulator AZD7325 in comparison with lorazepam in healthy males, British Journal of Clinical Pharmacology 78(6): 1298-1314.
- Guan, Z.; Chen, X.; Gerven, J.M.A. van; Hay, J.L. & Kam, M.D. (2014), STABILITY ANALYSIS OF CLUSTERING OF NORRIS' VISUAL ANALOG SCALE, British Journal of Clinical Pharmacology 78(4): 766-766.
- Khalili-Mahani, N.; Osch, M.J. van; Rooij, M. de; Beckmann, C.F.; Buchem, M.A. van; Dahan, A.; Gerven, J.M. van & Rombouts, S.A.R.B. (2014), Spatial heterogeneity of the relation between resting-state connectivity and blood flow: An important consideration for pharmacological studies, Human Brain Mapping 35(3): 929-942.
- Kleinloog, D.; Roozen, F.; Winter, W. de; Freijer, J. & Gerven, J. van (2014), Profiling the subjective effects of 9-tetrahydrocannabinol using visual analogue scales, International Journal of Methods in Psychiatric Research 23(2): 245-256.
- Cruz, H.G.; Hay, J.L.; Hoever, P.; Alessi, F.; Beek, E.T. te; Gerven, J.M.A. van & Dingemanse, J. (2014), Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine, European Neuropsychopharmacology 24(8): 1257-1268.
- Hoch, M.; Gorsel, H. van; Gerven, J. van & Dingemanse, J. (2014), Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant, Journal of Clinical Pharmacology 54(9): 979-986.
- Van Gerven J. M. A. & Hay J. L. (2014), Innovative tools for 'proof-of-pharmacological-concept' studies, European Neuropsychopharmacology 24: S150-S150.
- Cole D.M., Oei N.Y.L., Soeter R.P., Both S., Van Gerven J.M.A., Rombouts S.A.R.B. & Beckmann C.F. (2013), Dopamine-dependent architecture of cortico-subcortical network connectivity, Cerebral Cortex 23(7): 1509-1516.
- Khalili-Mahani N., Chang C., Van Osch M.J., Veer I.M., Van Buchem M.A., Dahan A., Beckmann C.F., Van Gerven J.M.A. & Rombouts S.A.R.B. (2013), The impact of "physiological correction" on functional connectivity analysis of pharmacological resting state fMRI, NEUROIMAGE 65: 499-510.
- Cole, D.M.; Oei, N.Y.L.; Soeter, R.P.; Both, S.; Gerven, J.M.A. van; Rombouts, S.A.R.B. & Beckmann, C.F. (2013), Dopamine-Dependent Architecture of Cortico-Subcortical Network Connectivity, Cerebral Cortex 23(7): 1509-1516.
- Cole, D.M.; Beckmann, C.F.; Oei, N.Y.L.; Both, S.; Gerven, J.M.A. van & Rombouts, S.A.R.B. (2013), Differential and distributed effects of dopamine neuromodulations on resting-state network connectivity, NeuroImage 78: 59-67.
- Hoch, M.; Hay, J.L.; Hoever, P.; Kam, M.L. de; Beek, E.T. te; Gerven, J.M.A. van & Dingemanse, J. (2013), Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans, European Neuropsychopharmacology 23(2): 107-117.
- Kuepper, R.; Ceccarini, J.; Lataster, J.; Os, J. van; Kroonenburgh, M. van; Gerven, J.M.A. van; Marcelis, M.; Laere, K. van & Henquet, C. (2013), Delta-9-Tetrahydrocannabinol-Induced Dopamine Release as a Function of Psychosis Risk: F-18-Fallypride Positron Emission Tomography Study, PLoS ONE 8(7).
- Klumpers, L.E.; Fridberg, M.; Kam, M.L. de; Little, P.B.; Jensen, N.O.; Kleinloog, H.D.; Elling, C.E. & Gerven, J.M.A. van (2013), Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects, British Journal of Clinical Pharmacology 76(6): 846-857.
- Khalili-Mahani, N.; Chang, C.; Osch, M.J. van; Veer, I.M.; Buchem, M.A. van; Dahan, A.; Beckmann, C.F.; Gerven, J.M.A. van & Rombouts, S.A.R.B. (2013), The impact of "physiological correction" on functional connectivity analysis of pharmacological resting state fMRI, NeuroImage 65: 499-510.
- Khalili-Mahani, N.; Chang, C.; Osch, M.J. van; Veer, I.M.; Buchem, M.A. van; Dahan, A.; Beckmann, C.F.; Gerven, J.M.A. van & Rombouts, S.A.R.B. (2013), The impact of "physiological correction" on functional connectivity analysis of pharmacological resting state fMRI, NeuroImage 65: 499-510.
- Hoch, M.; Hay, J.L.; Hoever, P.; Kam, M.L. de; Beek, E.T. te; Gerven, J.M.A. van & Dingemanse, J. (2013), Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans, European Neuropsychopharmacology 23(2): 107-117.
- Cole, D.M.; Oei, N.Y.L.; Soeter, R.P.; Both, S.; Gerven, J.M.A. van; Rombouts, S.A.R.B. & Beckmann, C.F. (2013), Dopamine-Dependent Architecture of Cortico-Subcortical Network Connectivity, Cerebral Cortex 23(7): 1509-1516.
- Cole, D.M.; Beckmann, C.F.; Oei, N.Y.L.; Both, S.; Gerven, J.M.A. van & Rombouts, S.A.R.B. (2013), Differential and distributed effects of dopamine neuromodulations on resting-state network connectivity, NeuroImage 78: 59-67.
- Kuepper, R.; Ceccarini, J.; Lataster, J.; Os, J. van; Kroonenburgh, M. van; Gerven, J.M.A. van; Marcelis, M.; Laere, K. van & Henquet, C. (2013), Delta-9-Tetrahydrocannabinol-Induced Dopamine Release as a Function of Psychosis Risk: F-18-Fallypride Positron Emission Tomography Study, PLoS ONE 8(7).
- Beek, E.T. te; Hay, J.L.; Bullman, J.N.; Burgess, C.; Nahon, K.J.; Klaassen, E.S.; Gray, F.A. & Gerven, J.M.A. van (2013), Pharmacokinetics and central nervous system effects of the novel dual NK1/NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers, British Journal of Clinical Pharmacology 75(5): 1328-1339.
- Beek, E.T. te; Tatosian, D.; Majumdar, A.; Selverian, D.; Klaassen, E.S.; Petty, K.J.; Gargano, C.; Dyck, K. van; McCrea, J.; Murphy, G. & Gerven, J.M.A. van (2013), Placebo- and Amitriptyline-Controlled Evaluation of Central Nervous System Effects of the NK1 Receptor Antagonist Aprepitant and Intravenous Alcohol Infusion at Pseudo-Steady State, Journal of Clinical Pharmacology 53(8): 846-856.
- Beek, E.T. te; Tatosian, D.; Majumdar, A.; Selverian, D.; Klaassen, E.S.; Petty, K.; Gargano, C.; Dyck, K. van; McCrea, J.; Murphy, G. & Gerven, J.M.A. van (2013), PLACEBO- AND AMITRIPTYLINE-CONTROLLED EVALUATION OF CENTRAL NERVOUS SYSTEM EFFECTS OF THE NK1 RECEPTOR ANTAGONIST APREPITANT AND INTRAVENOUS ALCOHOL INFUSION, British Journal of Clinical Pharmacology 76(5): 837-838.
- Liem-Moolenaar, M.; Peeters, P.; Kamerling, I.M.C.; Hogg, C.; Holder, G.; Kleijn, H.J.; Spaans, E.; Haes, J.U. de; Kam, M.L. de; Franson, K.L.; Cohen, A.F. & Gerven, J.M.A. van (2013), Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men, British Journal of Clinical Pharmacology 75(6): 1455-1467.
- Secilir, A.; Schrier, L.; Bijleveld, Y.A.; Toersche, J.H.; Jorjani, S.; Burggraaf, J.; Gerven, J. van & Mathot, R.A.A. (2013), Determination of methylphenidate in plasma and saliva by liquid chromatography/tandem mass spectrometry, Journal of Chromatography B 923: 22-28.
- Hoever, P.; Hay, J.; Rad, M.; Cavallaro, M.; Gerven, J.M. van & Dingemanse, J. (2013), Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Dose Almorexant, an Orexin Receptor Antagonist, in Healthy Elderly Subjects, Journal of Clinical Psychopharmacology 33(3): 363-370.
- Klumpers, L.E.; Roy, C.; Ferron, G.; Turpault, S.; Poitiers, F.; Pinquier, J.L.; Hasselt, J.G.C. van; Zuurman, L.; Erwich, F.A.S. & Gerven, J.M.A. van (2013), Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans, British Journal of Clinical Pharmacology 76(1): 65-77.
- Khalili-Mahani N., Zoethout R.M., Beckmann C.F., Baerends E.J., De Kam M.L., Soeter R.P., Dahan A., Van Buchem M.A., Gerven J.M. & Rombouts S.A.R.B. (2012), Effects of morphine and alcohol on functional brain connectivity during "resting state": a placebo-controlled crossover study in healthy young men, Human Brain Mapping 33(5): 1003-1018.
- Klumpers L.E., Cole D.M., Khalili-Mahani N., Soeter R.P., Te Beek E.T., Rombouts S.A.R.B. & Van Gerven J.M.A. (2012), Manipulating brain connectivity with O-tetrahydrocannabinol: A pharmacological resting state FMRI study, NEUROIMAGE 63(3): 1701-1711.
- Kleinloog, D.; Liem-Moolenaar, M.; Jacobs, G.; Klaassen, E.; Kam, M. de; Hijman, R. & Gerven, J. van (2012), Does olanzapine inhibit the psychomimetic effects of Delta(9)-tetrahydrocannabinol?, Journal of Psychopharmacology 26(10): 1307-1316.
- Haas, S.L. de; Zoethout, R.W.M.; Dyck, K. van; Smet, M. de; Rosen, L.B.; Murphy, M.G.; Gottesdiener, K.M.; Schoemaker, R.C.; Cohen, A.F. & Gerven, J.M.A. van (2012), The effects of TPA023, a GABA(A)alpha(2,3) subtype-selective partial agonist, on essential tremor in comparison to alcohol, Journal of Psychopharmacology 26(2): 282-291.
- Oei, N.Y.L.; Rombouts, S.A.R.B.; Soeter, R.P.; Gerven, J.M. van & Both, S. (2012), Dopamine Modulates Reward System Activity During Subconscious Processing of Sexual Stimuli, Neuropsychopharmacology 37(7): 1729-1737.
- Klumpers, L.E.; Cole, D.M.; Khalili-Mahani, N.; Soeter, R.P.; Beek, E.T. te; Rombouts, S.A.R.B. & Gerven, J.M.A. van (2012), Manipulating brain connectivity with delta(9)-tetrahydrocannabinol: A pharmacological resting state FMRI study, NeuroImage 63(3): 1701-1711.
- Beek, E.T.; Boer, P. de; Moerland, M.; Schmidt, M.; Hoetjes, N.; Windhorst, A.; Berckel, B. van; Cohen, A.; Gerven, J.M.A. van & Lammertsma, A. (2012), In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography., Journal of Psychopharmacology.
- Niesters, M.; Khalili-Mahani, N.; Martini, C.; Aarts, L.; Gerven, J. van; Buchem, M.A. van; Dahan, A. & Rombouts, S. (2012), Effect of Subanesthetic Ketamine on Intrinsic Functional Brain Connectivity A Placebo-controlled Functional Magnetic Resonance Imaging Study in Healthy Male Volunteers, Anesthesiology 117(4): 868-877.
- Haas, S.L. de; Zoethout, R.W.M.; Dyck, K. van; Smet, M. de; Rosen, L.B.; Murphy, M.G.; Gottesdiener, K.M.; Schoemaker, R.C.; Cohen, A.F. & Gerven, J.M.A. van (2012), The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol., Journal of Psychopharmacology 26(2): 282-91.
- Zoethout, R.W.M.; Iannone, R.; Bloem, B.R.; Palcza, J.; Murphy, G.; Chodakewitz, J.; Buntinx, A.; Gottesdiener, K.; Marsilio, S.; Rosen, L.; Dyck, K. van; Louis, E.D.; Cohen, A.F.; Schoemaker, R.C.; Tokita, S.; Sato, N.; Koblan, K.S.; Hargreaves, R.H.; Renger, J.J. & Gerven, J.M.A. van (2012), The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol., Journal of Psychopharmacology 26(2): 292-302.
- Cella, M.; Knibbe, C.; Wildt, S.N. de; Gerven, J. van; Danhof, M. & Pasqua, O. della (2012), Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models., British Journal of Clinical Pharmacology.
- Khalili-Mahani, N.; Zoethout, R.M.W.; Beckmann, C.F.; Baerends, E.; Kam, M.L. de; Soeter, R.P.; Dahan, A.; Buchem, M.A. van; Gerven, J.M.A. van & Rombouts, S.A.R.B. (2012), Effects of morphine and alcohol on functional brain connectivity during "resting state": A placebo-controlled crossover study in healthy young men, Human Brain Mapping 33(5): 1003-1018.
- Beek, E.T.T.; Zoethout, R.W.M.; Bani, M.S.G.; Andorn, A.; Iavarone, L.; Klaassen, E.S.; Fina, P. & Gerven, J.M.A. van (2012), Pharmacokinetics and central nervous system effects of the novel dopamine D-3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state, Journal of Psychopharmacology 26(2): 303-314.
- Liem-Moolenaar M., Boer P. de, Timmers M., Schoemaker R.C., Hasselt J.G.C. van, Schmidt S. & Gerven J.M.A. van (2011), Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects, British Journal of Clinical Pharmacology 71(6): 886-898.
- Jacobs, G.E.; Gerven, J.M.A. van; Kam, M.L. de; Elassaiss-Schaap, J.; Ruigt, G.; Pelt, J. van; Peeters, B.W.M.M.; Peeters, P.A.M. & Hulskotte, E.G.J. (2011), A pharmacological tool to assess vasopressinergic co-activation of the hypothalamus-pituitary-adrenal axis more integrally in healthy volunteers, Journal of Psychopharmacology 25(3): 361-369.
- Jacobs, G.E.; Hulskotte, E.G.J.; Gerven, J.M.A. van; Zuurman, L.; Kam, M.L. de; Elassaiss-Schaap, J.; Ruigt, G.; Pelt, J. van; Peeters, B.W.M.M.; Peeters, P.A.M. & Burggraaf, J. (2011), Desmopressin as a pharmacological tool in vasopressinergic hypothalamus-pituitary-adrenal axis modulation: neuroendocrine, cardiovascular and coagulatory effects, Journal of Psychopharmacology 25(3): 353-360.
- Beek, E.T. te; Moerland, M.; Boer, P. de; Nueten, L. van; Kam, M.L. de; Burggraaf, J.; Cohen, A.F. & Gerven, J.M.A. van (2011), Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681., Journal of Psychopharmacology.
- Klumpers LE, Beumer TL, van Hasselt JG, Lipplaa A, Karger LB, Kleinloog HD, Freijer JI, de Kam ML & van Gerven JM (2011), Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects., British Journal of Clinical Pharmacology.
- Liem-Moolenaar, M.; Rad, M.; Zamuner, S.; Cohen, A.F.; Lemme, F.; Franson, K.L.; Gerven, J.M.A. van & Pich, E.M. (2011), Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men., British Journal of Clinical Pharmacology 71(6): 907-16.
- Khalili-Mahani, N.; Osch, M.J.P. van; Baerends, E.; Soeter, R.P.; Kam, M. de; Zoethout, R.W.M.; Dahan, A.; Buchem, M.A. van; Gerven, J.M.A. van & Rombouts, S.A.R.B. (2011), Pseudocontinuous arterial spin labeling reveals dissociable effects of morphine and alcohol on regional cerebral blood flow., Journal of Cerebral Blood Flow and Metabolism.
- Liem-Moolenaar, M.; Boer, P. de; Timmers, M.; Schoemaker, R.C.; Hasselt, J.G.C. van; Schmidt, S. & Gerven, J.M.A. van (2011), Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects, British Journal of Clinical Pharmacology 71(6): 886-898.
- Jepma, M.; Beek, E.T.T.; Wagenmakers, E.J.; Gerven, J.M.A. van & Nieuwenhuis, S. (2010), The role of the noradrenergic system in the exploration-exploitation trade-off: a psychopharmacological study, Frontiers in Human Neuroscience 4: -.
- Jacobs, G.E.; Grond, J. van der; Teeuwisse, W.M.; Langeveld, T.J.C.; Pelt, J. van; Verhagen, J.C.M.; Kam, M.L. de; Cohen, A.F.; Zitman, F.G. & Gerven, J.M.A. van (2010), Hypothalamic glutamate levels following serotonergic stimulation: A pilot study using 7-Tesla magnetic resonance spectroscopy in healthy volunteers, Progress in Neuro-Psychopharmacology and Biological Psychiatry 34(3): 486-491.
- Jacobs, G.E.; Hulskotte, E.G.J.; Kam, M.L. de; Zha, G.; Jiang, J.; Hu, P.; Zhao, Q.; Pelt, J. van; Goekoop, J.G.; Zitman, F.G. & Gerven, J.M.A. van (2010), Metoclopramide as pharmacological tool to assess vasopressinergic co-activation of the hypothalamus-pituitary-adrenal (HPA) axis: A study in healthy volunteers, European Neuropsychopharmacology 20(12): 866-874.
- Wirtz, P.W.; Titulaer, M.J.; Gerven, J.M.A. van & Verschuuren, J.J. (2010), 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome, Expert Review of Clinical Immunology 6(6): 867-874.
- Liem-Moolenaar, M.; Gray, F.A.; Visser, S.J. de; Franson, K.L.; Schoemaker, R.C.; Schmitt, J.A.J.; Cohen, A.F. & Gerven, J.M.A. van (2010), Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol., Journal of Psychopharmacology 24(1): 73-82.
- Wirtz P.W., Verschuuren J.J., Dijk J.G. van, Kam M.L. de, Schoemaker R.C., Hasselt J.G.C. van, Titulaer M.J., Tjaden U.R., Hartigh J. den & Gerven J.M.A. van (2009), Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study, Clinical Pharmacology & Therapeutics 86(1): 44-48.
- Dumont G.J.H., Kramers C., Sweep F.C., Touw D.J., Hasselt J.G.C. van, Kam M.L. de, Gerven J.M.A. van, Buitelaar J.K. & Verkes R.J. (2009), Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans, Clinical Pharmacology & Therapeutics 86(2): 160-166.
- Munts AG, van der Plas AA, Voormolen JH, Marinus J, Teepe-Twiss IM, Onkenhout W, van Gerven JM & van Hilten JJ (2009), Intrathecal glycine for pain and dystonia in complex regional pain syndrome., PAIN 146(1-2): 199-204.
- Wirtz PW, Verschuuren JJ, van Dijk JG, de Kam ML, Schoemaker RC, van Hasselt JGC, Titulaer MJ, Tjaden UR, den Hartigh J & van Gerven JMA (2009), Efficacy of 3,4-Diaminopyridine and Pyridostigmine in the Treatment of Lambert-Eaton Myasthenic Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study, Clinical Pharmacology and Therapeutics 86(1): 44-48.
- Jacobs GE, van der Grond J, Teeuwisse W, Langeveld T & van Gerven JMA (2009), 7-TESLA FUNCTIONAL PROTON MAGNETIC RESONANCE SPECTROSCOPY OF SEROTONERGIC HYPOTHALAMIC ACTIVATION IN HEALTHY VOLUNTEERS, Basic and Clinical Pharmacology and Toxicology 105: 24-25.
- Munts AG, van der Plas AA, Voormolen JH, Marinus J, Teepe-Twiss IM, Onkenhout W, van Gerven JM & van Hilten JJ (2009), Intrathecal glycine for pain and dystonia in complex regional pain syndrome, PAIN 146(1-2): 199-204.
- Klein HR, Schneider TC, Schrier L, de Kam ML, van Gerven JMA, Sukhai RN, Pereira RR, Wit JM, Burggraaf J & Cohen AF (2009), A RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH METHYLPHENIDATE TO INVESTIGATE ACUTE DRUG EFFECTS ON A SET OF NEUROCOGNITIVE TASKS, Basic and Clinical Pharmacology and Toxicology 105: 128-129.
- Zuurman L., Roy C., Schoemaker R.C., Hazekamp A., Den Hartigh J., Bender J.C.M.E., Verpoorte R., Pinquier J., Cohen A.F. & Gerven J.M.A. van (2008), Effect of intrapulmonary tetrahydrocannabinol administration in humans, Journal of Psychopharmacology 22: 707-716.
- Smarius LJCA, Jacobs GE, Hoeberechts-Lefrandt DHM, de Kam ML, van der Post JP, de Rijk R, van Pelt J, Schoemaker RC, Zitman FG, van Gerven JMA & Gijsman HJ (2008), Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa, Journal of Psychopharmacology 22(4).
- Dumont GJH, Verkes RJ, Buitelaar JK & van Gerven JMA (2008), Response to the comments by Cassel et al., Psychopharmacology 200(3).
- Hoever P, de Haas S, Chiossi E, van Gerven J & Dingemanse J (2008), Multiple-dose pharmacokinetics, pharmacodynamics, safety, and tolerability of the orexin receptor antagonist almorexant in healthy subjects, SLEEP 31.
- Dumont GJH, Wezenberg E, Valkenberg MMGJ, De Jong CAJ, Buitelaar JK, Van Gerven JMA & Verkes RJ (2008), Acute neuropsychological effects of MDMA and ethanol (co-)administration in healthy volunteers, Psychopharmacology 197(3).
- Lansbergen MM, Dumont GJH, Buitelaar JK, van Gerven JMA & Verkes RJ (2008), Alertness and electrocortical activity after (co-)administration of MDMA and THC in healthy volunteers, European Neuropsychopharmacology 18.
- Gerven J.M.A. van (2007), Behandeling van neuropathische pijn. Boerhaave Instituut. [overig].
- Zuurman L., Roy C., Asset G., Amatsaleh A., Guimaraes L., Pinquier J., Cohen A.F. & Gerven J.M.A. van (2007), The effects of the novel CB1 antagonist AVE1625 on the THC-induced changes on central nervous system effects and heart rate, Clinical Pharmacology & Therapeutics 81(suppl 1:S4): .
- Kasteleijn-Nolst Trenité D.G.A., French J.A., Hirsch E., Macher J.P., Meyer B.U., Grosse P.A., Abou-Khalil B.W., Rosenfeld W.E., Gerven J.M.A. van, Novak G.P., Parmeggiani L., Schmidt B., Gibson D. & Guerrini R. (2007), Evaluation of carisbamate, a novel antiepileptic drug, in photosensitive patients: an exploratory, placebo-controlled study, Epilepsy Research 74: 193-200.
- Brisbane-Roch C., Dingemanse J., Koberstein R., Hoever P., Aissaoui H., Flores S., Mueller C., Gerven J.M.A. van, Haas S.L. de, Hess P., Qiu C., Buchmann S., Scherz M., Weller T., Fischli W., Clozel M. & Jenck F. (2007), Promotion of sleep by targeting the orexin system in rats, dogs and humans, Nature Medicine 13: 150-155.
- Haas S. de, Otte A., Weerd A. de, Erp G. van, Cohen A.F. & Gerven J.M.A. van (2007), Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy, Journal of clinical sleep medicine 3: 473-478.
- Haas S. de, Dingemanse J., Hoever P., Cohen A.F. & Gerven J.M.A. van (2007), Pseudo-hallucinations after zolpidem intake: A case report, 27: 728-730.
- Zuurman L, Roy C, Schoemaker RC, Asset G, Amatsaleh A, Guimaraes L, Pinquier J, Cohen AF & van Gerven JM (2007), The effects of the novel CB1 antagonist AVE1625 on THC-induced changes on central nervous system effects and heart rate., Clinical Pharmacology and Therapeutics 81.
- Dumont GJH, Valkenberg MMGJ, Schoemaker R, Buitelaar JK, van Gerven JMA & Verkes RJ (2007), Acute MDMA and ethanol interaction effects on psychomotor performance, British Journal of Clinical Pharmacology 63(4).
- Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, van Gerven J, de Haas SL, Hess P, Qiu CB, Buchmann S, Scherz M, Weller T, Fischli W, Clozel M & Jenck F (2007), Promotion of sleep by targeting the orexin system in rats, dogs and humans, Nature Medicine 13(2).
- de Haas SL, de Visser SJ, de Kam ML, de Smet M, Murphy G, Vessey L, Cohen AF & van Gerven JM (2007), The selective central nervous system (CNS) effects of two different GABA(A) alpha(2, 3) subtype-selective agonists compared to lorazepam., Clinical Pharmacology and Therapeutics 81.
- Dumont G, Schoenmaker R, van Gerven JMA, Buitelaar JK & Verkes RJ (2007), Ecstasy and ethanol interaction effects on psychomotor function, European Neuropsychopharmacology 17.
- Rijneveld JM, Rad M, ter Kuile MM, de Kam ML, Both S, Weijenborg PT & van Gerven JM (2007), Safety, tolerability and pharmacokinetics of a single intravaginal dose of rec 15/2615, a topical alpha(1)-antagonist in healthy female volunteers., Clinical Pharmacology and Therapeutics 81.
- Zuurman L, Passier PC, de Kam M, Kleijn HJ, Cohen AF & van Gerven JM (2007), Pharmacokinetic and pharmacodynamic effects of the intravenously administered CB1 receptor agonist org 28611 in healthy male volunteers., Clinical Pharmacology and Therapeutics 81.
- Trenite DGAKN, French JA, Hirsch E, Macher JP, Meyer BU, Grosse PA, Abou-Khalil BW, Rosenfeld WE, van Gerven J, Novak GP, Parmeggiani L, Schmidt B, Gibson D & Guerrini R (2007), Evaluation of carisbamate, a novel antiepileptic drug, in photosensitive patients: An exploratory, placebo-controlled study, Epilepsy Research 74(2-3).
- Jacobs GE, Hoeberechts-Lefrandt LJCA, De Kam ML, Zitman FG & Van Gerven JMA (2007), Tolerability of the 5-hydroxytryptophane challenge test with granisetron and domperidone, European Neuropsychopharmacology 17.
- Zuurman L, Roy C, Schoemaker RC, Asset G, Amatsaleh A, Guimaraes L, Pinquier JL, Cohen AF & van Gerven JMA (2007), Inhibition of THC-induced effects on central nervous system effects and heart rate by a novel CB1 receptor antagonist AVE1625, British Journal of Clinical Pharmacology 63(6).
- Hazekamp A., Ruhaak R., Zuurman L., Gerven J.M.A. van & Verpoorte R. (2006), Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol, JOURNAL OF PHARMACEUTICAL SCIENCES 95: 1308-1317.
- Haas S. de, Visser S.J. de, Post J.P. van der, Smet M. de, Schomaker R.C., Rijnbeek B., Cohen A.F., Vega J., Agrawal N.G., Goel T.V., Simpson R.C., Pearson L.K., Li S., Hesney M., Murphy M. & Gerven J.M.A. van (2006), The selective effects of two different GABA A Alpha2,3 subtype-selecctive agonist compared to lorazepam, Journal of Psychopharmacology A15: .
- Haas S. de, Visser S.J. de, Post J.P. van der, Smet M. de, Schomaker R.C., Rijnbeek B., Cohen A.F., Vega J., Agrawal N.G., Goel T.V., Simpson R.C., Pearson L.K., Li S., Hesney M., Murphy M. & Gerven J.M.A. van (2006), Pharmacodynamic effects of TPA023, a GABA-A subtype selective agonist, compared with lorazepam and placebo in healthy volunteers, Br.J.Clin.Pharmacol. 61(5): 627.
- Haas S., Visser S.J. de, Post J.P. van der, Smet M. de, Schomaker R.C., Rijnbeek B., Cohen A.F., Vega J., Agrawal N.G., Goel T.V., Simpson R.C., Pearson L.K., Hesney M., Murphy M. & Gerven J.M.A. van (2006), Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA {alpha}2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers, Journal of Psychopharmacology : .
- Hazekamp, A.; Ruhaak, R.; Zuurman, L.; Gerven, J. van & Verpoorte, R. (2006), Evaluation of a vaporizing device (Volcano (R)) for the pulmonary administration of tetrahydrocannabinol, Journal of Pharmaceutical Sciences 95(6).
- Zuurman L., Roy C., Schoemaker H.C., Hartigh J. den, Bender J.C.M.E., Pinquier J., Cohen A.F. & Gerven J.M.A. van (2005), Effect of THC administration in humas: methodology study for further pharmacodynamic studies with cannabinoid agonist or antagonist, British Journal of Clinical Pharmacology 59(5): 625.
- Dumont G.J.H., Visser S.J. de, Cohen A.F. & Gerven J.M.A. van (2005), Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects, British Journal of Clinical Pharmacology 59: 495-510.
- Post J.P. van der, Visser S.J. de, Kam M.L. de, Woelfler M., Hilt D.C., Vornov J., Burak E.S., Bortey E., Slusher B.S., Limsakun T., Cohen A.F. & Gerven J.M.A. van (2005), The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693, British Journal of Clinical Pharmacology 60: 128-136.
- Dumont G.J.H., Visser S.J. de, Cohen A.F. & Gerven J.M.A. van (2005), Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy volunteers, British Journal of Clinical Pharmacology 59: 495-510.
- Dumont GJH, de Visser SJ, Cohen AF & van Gerven JMA (2005), Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects, British Journal of Clinical Pharmacology 59(5).
- Post J.P. van der, Waal P.P. de, Kam M.L. de, Cohen A.F. & Gerven J.M.A. van (2004), No evidence of the usefulness of eye blinking as a marker for central dopaminergic activity, Journal of Psychopharmacology 18: 109-114.
- Post J.P. van der, Visser S.J. de, Kam M.L. de, Woelfler M., Hilt D.C., Vornov J., Burak E.S., Bortey E., Slusher B.S., Limsakun T., Cohen A.F. & Gerven J.M.A. van (2004), The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693, British Journal of Clinical Pharmacology : .
- Dubois E.A., Franson K.L., Gerven J.M.A. van, Bolk J.H. & Cohen A.F. (2004), Integration of training in pharmacology and pharmacotherapy in the medical curriculum in Leiden, the Netherlands, Nederlands Tijdschrift voor Geneeskunde 148(4): 194-199.
- Post J.P. van der, Visser S.J. de, Schoemaker R.C., Cohen A.F. & Gerven J.M.A. van (2004), Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of 1 3 mg sustained release tablet of rilmenidine in hypertensive patients, Journal of Psychopharmacology 18: 221-227.
- van der Post J, de Waal PP, de Kam ML, Cohen AF & van Gerven JMA (2004), No evidence of the usefulness of eye blinking as a marker for central dopaminergic activity, Journal of Psychopharmacology 18(1).
- van der Post JP, de Visser SJ, Schoemaker RC, Cohen AF & van Gerven JMA (2004), Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients, Journal of Psychopharmacology 18(2).
- Kemme M.J.B., Post J. van der, Schoemaker R.C., Straub M., Cohen A.F. & Gerven J.M.A. van (2003), Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension, British Journal of Clinical Pharmacology 55: 518-525.
- Haas S. de, Weerd A.W. de, Otte A., Kasteleijn-Nolst Trenité D.G., Gerven J.M.A. van, Erp G., Kam M. de & Cohen A.F. (2003), Epidemiologie van slaapproblemen bij patienten met partiele epilepsie, Tijdschrift voor Neurologie en Neurochirurgie 104: 16-17.
- Pieters M.S.M., Steveninck A.F., Schoemaker R.C., Kroon J.M., Gerven J.M.A. van & Cohen A.F. (2003), The psychomotor effects of carbamazepine in epileptic patients and healthy volunteers, Journal of Psychopharmacology 17(3): 269-272.
- Visser S.J. de, Post J. van der, Waal P.P. de, Cornet F., Cohen A.F. & Gerven J.M.A. van (2003), Biomarkers for the effects of benzodiazepines in healthy volunteers, British Journal of Clinical Pharmacology 55: 39-50.
- Rijnbeek B, de Visser SJ, Franson KL, Cohen AF & van Gerven JMA (2003), REM sleep effects as a biomarker for the effects of antidepressants in healthy volunteers, Journal of Psychopharmacology 17(2).
- Pieters MSM, van Steveninck AF, Schoemaker RC, Kroon JM, van Gerven JMA & Cohen AF (2003), The psychomotor effects of carbamazepine in epileptic patients and healthy volunteers, Journal of Psychopharmacology 17(3).
- Post J.A.M. van der, Noordzij L.A.W., Kam M.L. de, Blauw G.J., Cohen A.F. & Gerven J.M.A. van (2002), Evaluation of tests of central nervous system performance after hypoxemia for a model for cognitive impairment, J Psychopharmacol 16: 337-343.
- Post J. van der, Noordzij L.A.W., Kam M.L. de, Blauw G.J., Cohen A.F. & Gerven J.M.A. van (2002), Evaluation of tests of central nervous system performance after hypoxia for a model for cognitive impairment, Journal of Psychopharmacology 16: 337-343.
- Gijsman HJ, van Gerven JMA, Verkes RJ, Schoemaker RC, Pieters MSM, Pennings EJM, Hessing TJ & Cohen AF (2002), Saccadic peak velocity and EEG as end-points for a serotonergic challenge test, Human Psychopharmacology: Clinical and Experimental 17(2).
- Verkes RJ, Gijsman HJ, Pieters MSM, Schoemaker RC, de Visser S, Kuijpers M, Pennings EJM, de Bruin D, Van de Wijngaart G, Van Gerven JMA & Cohen AF (2001), Cognitive performance and serotonergic function in users of ecstasy, Psychopharmacology 153(2).
- Roode A. de, Gerven J.M.A. van, Schoemaker R.C., Engbers F.H.M., Olieman W., Kroon J.R., Cohen A.F. & Bovill J.G. (2000), A comparison of the effects of propofol and midazolam on memory during two levels of sedation by using target-controlled infusion, Anesthesia and Analgesia 91: 1056-1061.
- Gijsman HJ, Verkes RJ, Schouten-Verhagen JCM, Schoemaker RC, Van Gerven JMA, De Rijk RH & Van Kempen GMJ (2000), Estimation of plasma serotonin using isopycnic centrifugation, Human Psychopharmacology: Clinical and Experimental 15(6).
- Steveninck A.L. van, Berckel B.N.M. van, Schoemaker R.C., Breimer D.D., Gerven J.M.A. van & Cohen A.F. (1999), The sensitivity of pharmacodynamic tests for central nervous system effects of drugs on the effects of sleep deprivation, Journal of Psychopharmacology 3: 10-17.
- Lammers G.J., Dijk J.G. van, Ferrari M.D., Gerven J.M.A. van, Declerck A.C. & Troost J. (1999), Gammahydroxyboterzuur dient beschikbaar te blijven voor patiënten met narcolepsie, Nederlands Tijdschrift voor Geneeskunde 143: 2062-2063.
- Haarst A.D. van, Gerven J.M.A. van, Cohen A.F., Smet M. de, Sterrett A., Brik K.L., Fisher A.L., Puy M.E. de, Goldberg M.R. & Musson D.G. (1999), The effects of moclobemide on the pharmacokinetics of the 5-HT1b/1d agonist rizatriptan in healthy volunteers, British Journal of Clinical Pharmacology 48: 190-196.
- Faaij R.A., Gerven J.M.A. van, Jolivet-Landreau I., Masclee A.A.M., Vendrig E.M., Schoemaker R.C., Jacobs L.D. & Cohen A.F. (1999), Onset of action during on-demand treatment with Maalox suspension or low-dose ranitidine for heartburn, Alimentary Pharmacology and Therapeutics 13(12): 1605-1610.
- Gijsman H.J., Gerven J.M.A. van, Tieleman M.C., Schoemaker R.C., Pieters M.S.M., Ferrari M.D., Cohen A.F. & Kempen G.M.J. van (1998), Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers, International Clinical Psychopharmacology 18: 289-295.
- Gerven J.M.A. van, Uchida E., Uchida N., Pieters M.S.M., Meinders A.J., Schoemaker R.C., Nanhekhan L.V., Visser S.J. de, Altorf B., Yasuda K., Yasuhara H. & Cohen A.F. (1998), Pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy male and female volunteers. An interethnic comparative study between Japanese and Caucasian volunteers, The Journal of Clinical Pharmacology 38: 1129-1136.
- Verkes R.J., Gijsman H.J., Pieters M.S.M., Pennings E.J.M., Schoemaker R.C., Gerven J.M.A. van & Cohen A.F. (1998), Cognitive and serotonergic function in exstasy-users and controls. onbekend: LUMC.
- Gerven J.M.A. van, Gijsman H.J., Verkes R.J. & Cohen A.F. (1998), Cognitieve en psychotische effecten na stopzetting van chronisch cannabisgebruik, Nederlands Tijdschrift voor Geneeskunde 142: 1046-1047.
- Gerven J.M.A. van, Gijsman H.J., Verkes R.J. & Cohen A.F. (1998), Cognitieve en psychotische effecten na stopzetting van chronisch cannabisgebruik, Nederlands Tijdschrift voor Geneeskunde 142: 1046-1047.
- Schoemaker R.C., Gerven J.M.A. van & Cohen A.F. (1998), Estimating potency for the Emax-model without attaining maximal effects, Journal of Pharmacokinetics and Biopharmaceutics 26: 581-593.
- Gijsman H.J., Gerven J.M.A. van, Tieleman M.C., Schoemaker H.C., Pieters M.S.M., Ferrari M.D., Cohen A.F. & Kempen G.M.J. van (1998), Pharmacokinetic and pharmacodynamic profile of oral and intravenous metachlorophenylpiperazine in healthy volunteers, 18(4): 289-295.
- Haarst A.D. van, Klooster G.A.E., Gerven J.M.A. van, Schoemaker H.C., Oene J.C. van, Burggraaf J., Coene M.-C. & Cohen A.F. (1998), The influence of cisapride and clarithromycin on QT intervals in healthy volunteers, Clinical Pharmacology & Therapeutics 64: 542-546.
- Gerven J.M.A. van, Ychida E. & Pieters M.S.M. (1998), Pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy male and female volunteers: an interethnic comparative study of Japanese and Caucasian volunteers, British Journal of Clinical Pharmacology 45: 183-215.
- Gerven J.M.A. van, Uchida E., Uchida N., Pieters M.S.M., Meinders A.J., Schoemaker H.C., Nanhekhan L.V., Visser S.J. de, Altorf B., Yasuda K., Yasuhara H. & Cohen A.F. (1998), Pharmacodynamic and pharmacokinetics of a single oral dose of nitrazeam in healthy volunteers: an interethnic comparative study between Japanese and European volunteers, The Journal of Clinical Pharmacology 38: 1129-1136.
- Steyerberg E.W., Keizer H.J., Messemer J.E., Toner G.C., Schraffordt Koops H., Fossa S.D., Gerven J.M.A. van, Sleyfer D.T., Donohue J.P. & Habbema J.D.F. (1997), Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor, Cancer 79: 345-355.
- internationaal redactielid
- voorzitter
- research director